NYSE
$0.2434▲ 1.42%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.7MShares out 44.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 1d agoAfter-hours26.10.24 05:158-KKey event#●●●#●●●
AEON Biopharma, Inc.
AEON Biopharma released a corporate presentation on October 23, 2026, detailing the development progress of its neurotoxin candidate, ABP-450. The company has received FDA feedback regarding its CMAP pharmacodynamic study and plans to submit an IND in Q4 2026, with study initiation expected in Q1 2027.…more
$0.2434+1.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 06:24PRE 14AOther
AEON Biopharma, Inc.
AEON Biopharma will hold a Special Meeting of Stockholders on December 15, 2026, to vote on a proposal for a reverse stock split at a ratio ranging from 1-for-2 to 1-for-100. The reverse split is intended to maintain compliance with NYSE American listing standards, alongside proposals to amend equity incentive and employee stock purchase plans regarding dilution calculations.…more
$0.2434+1.42%vs prev closeView filingShare - 9.30Pre-market26.09.30 21:008-KKey event
AEON Biopharma, Inc.
AEON Biopharma received official minutes from its FDA Type 2b meeting, clarifying the development pathway for its ABP-450 biosimilar. The company plans to submit an IND in Q4 2026 and initiate a CMAP pharmacodynamic study in Q1 2027, while the expiration date for its July 2026 two-year milestone warrants has been accelerated to November 16, 2026.…more
$0.2434+1.42%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9After-hours26.10.10 05:15#●●●
AEON Biopharma Grants Inducement Equity to New Employee
AEON Biopharma has granted 150,000 restricted stock units (RSUs) to a newly hired non-executive employee. This award serves as a standard employment inducement incentive for talent acquisition.…more
$0.2434+1.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 21:01
●●●●●●●● ●●●●● ●●●●●●
AEON Biopharma can now submit prior head-to-head study data against Botox as supportive evidence for its ABP-450 biosimilar. This regulatory clarity reduces development hurdles and improves the pathway toward potential FDA approval.…more
$0.2434+1.42%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 21:03
●●●●●●●● ●●●●● ●●●●●●
AEON Biopharma announced that its ABP-450 candidate demonstrated similar potency loss and oxidation patterns to AbbVie's Botox under thermal stress. The company plans to conduct a multi-lot comparability study in the first half of 2027.…more
$0.2434+1.42%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report